novo nordisk oral semaglutide to Seek Approval for Pill to Treat Diabetes in Young Patients Business | Novo Nordisk has
Description
When blood sugar stands-up, GLP-1 receptor agonists help our insulin to also stand-up
The FDA intends to remove questionable active ingredients from the GLP-1 drug market
The STEP 1 trial studied semaglutide 2.4 mg weekly in adults without diabetes and found 14.9% mean body weight loss versus 2.4% with placebo at 68 weeks
What is surprising is the slowing of the progression of kidney disease
Popular technologies include: Ultherapy (micro-focused ultrasound)
